Pascal Hammel
Pascal Hammel is an expert in Gastroenterology at Assistance Publique - Hôpitaux de Paris (France). As of October 2026, ScienceLeadR ranks Pascal Hammel in the top 1% of experts worldwide for Pancreatic Neoplasms, Pancreatic Diseases and Endocrine Gland Neoplasms. Pascal Hammel has authored 599 publications, the most recent in 2026, and is an investigator in 42 clinical trials, 12 of them ongoing. SLR score: 2,585 (community average: 125). How the SLR is computed.
LeadR Profile
Gastroenterology
Subspecialties: Oncology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1990 - 2026
Number : 599
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Is Cytoreductive surgery for unresectable colorectal liver metastases able to improve patient outcome? Results of a pilot prospective study. PMID 42561547 — pilots, cytoreduction surgical procedures, drug therapy, liver, hepatectomy, neoplasm metastasis, prospective studies, chemotherapy | Cancer Treat Rev | 2026 | 0 |
| Impact of Tumor Genomic Profile on Adjuvant Chemotherapy Efficacy in Resected Pancreatic Adenocarcinoma: Results From the PRODIGE-24/CCTG PA6 Study. PMID 42546248 — genes, neoplasms, adenocarcinoma, drug therapy, chemotherapy, adjuvant, recombinational dna repair, therapeutics, medical oncology, chemotherapy | J Clin Oncol Top journal | 2026 | 1 |
| Developing a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancer. PMID 42507965 — intelligence, pancreatic neoplasms, neoplasms, drug therapy, biomarkers, chemotherapy, adjuvant, deep learning, histology, therapeutics, medical oncology, learning, artificial intelligence, chemotherapy | J Clin Oncol Top journal | 2026 | 1 |
| ASO Visual Abstract: Is R1 Extended Liver Resection for Locally Advanced Intrahepatic Cholangiocarcinoma Justified? Nodal Status Not Margin Drives Prognosis. PMID 42406213 — liver, prognosis, cholangiocarcinoma, intrahepatic cholangiocarcinoma | Ann Surg Oncol | 2026 | 0 |
| Emergency integrative supportive care program for frail patients with advanced pancreatic cancer: A prospective GERCOR ARCAD study. PMID 42396273 — quality of life, pancreatic neoplasms, emergencies, pain, neoplasms, drug therapy, fluorouracil, therapeutics, chemotherapy | medRxiv | 2026 | 0 |
Clinical Studies 42
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
12 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Phase 3 study of RMC 6236 in patients with previously treated metastatic PDAC 2024-516063-89-00 — adenocarcinoma, therapeutics | Phase 3 | Active not recruiting | 2025 |
| Roll Over Study for Patients Who Have Completed a Previous Oncology Study with Olaparib 2024-512982-15-00 — pancreatic neoplasms, breast neoplasms, endometrium, ovary, neoplasms, prostate, ovarian neoplasms, breast, prostatic neoplasms, therapeutics | Phase 3 | Not yet recruiting | 2021 |
| A study of BMS 986504 in combination with Nab p Gem versus placebo in combination with Nab p Gem in untreated metastatic PDAC with homozygous MTAP deletion 2025-522598-12-00 — paclitaxel, adenocarcinoma | Phase 2/Phase 3 | Recruiting | 2025 |
| Gut microbiome intervention with EXL01 in combination with nivolumab and FOLFOX as first line treatment for patients with PD L1 CPS 5 metastatic gastric cancer A randomized GERCOR phase II study (BIG) 2023-506753-38-00 — neoplasms, adenocarcinoma, nivolumab, therapeutics, gastrointestinal microbiome, stomach neoplasms | Phase 2 | Recruiting | 2024 |
| Sotorasib combined with first line chemotherapy for advanced pancreatic adenocarcinoma 2024-516233-12-00 — adenocarcinoma, drug therapy, mutation, chemotherapy | Phase 1 | Recruiting | 2025 |
LeadR Networks
Main global connection map